Arcadia Biosciences Statistics
Want to see RKDA full AI Analyst Report?
Arcadia Biosciences (RKDA) Stock Statistics & Valuation Metrics
Total Valuation
Arcadia Biosciences has a market cap or net worth of $397.52K. The enterprise value is -$2.15M.
- Market Cap
- $397.52K
- Enterprise Value
- -$2.15M
Share Statistics
Arcadia Biosciences has 2,409,211 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,409,211
- Owned by Insiders
- ―
- Owned by Institutions
- 1.45%
Financial Efficiency
Arcadia Biosciences’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -222.75%.
- Return on Equity (ROE)
- -0.56
- Return on Assets (ROA)
- -0.36
- Return on Invested Capital (ROIC)
- -222.75%
- Return on Capital Employed (ROCE)
- -2.23
- Revenue Per Employee
- 607.25K
- Profits Per Employee
- -292.38K
- Employee Count
- 8
- Asset Turnover
- 0.74
- Inventory Turnover
- 2.56
Valuation Ratios
The current PE Ratio of Arcadia Biosciences is -0.03. Arcadia Biosciences’s PEG ratio is 0.00.
- PE Ratio
- -0.03
- PS Ratio
- 0.08
- PB Ratio
- 0.51
- Price to FCF
- -0.15
- Price to Operating Cash Flow
- -0.13
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Arcadia Biosciences had revenue of 4.86M and earned -2.34M in profits. Earnings per share was -1.71.
- Revenue
- 4.86M
- Gross Profit
- 1.76M
- Operating Income
- -9.99M
- Pretax Income
- -2.33M
- Net Income
- -2.34M
- EBITDA
- -2.30M
- Earnings Per Share (EPS)
- -1.71
Cash Flow
In the last 12 months, operating cash flow was -2.54M and capital expenditures 0, giving a free cash flow of -2.54M billion.
- Operating Cash Flow
- -2.54M
- Free Cash Flow
- -2.54M
- Free Cash Flow per Share
- -1.85
Dividends & Yields
Arcadia Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -688.64%
- Earnings Yield
- -3418.64%
Stock Price Statistics
- Beta
- 1.78
- 52-Week Price Change
- -93.52%
- 50-Day Moving Average
- 0.30
- 200-Day Moving Average
- 0.93
- Relative Strength Index (RSI)
- 59.12
- Average Volume (3m)
- 2.21M
Important Dates
Arcadia Biosciences upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Arcadia Biosciences as a current ratio of 3.09, with Debt / Equity ratio of 0.00%
- Current Ratio
- 3.09
- Quick Ratio
- 2.50
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.11
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Arcadia Biosciences has paid 8,000 in taxes.
- Income Tax
- 8,000
- Effective Tax Rate
- -0.00
Enterprise Valuation
Arcadia Biosciences EV to EBITDA ratio is 0.34, with an EV/FCF ratio of 1.50.
- EV to Sales
- -0.80
- EV to EBITDA
- 0.34
- EV to Free Cash Flow
- 1.50
- EV to Operating Cash Flow
- 1.50
Balance Sheet
Arcadia Biosciences has $4.18M in cash and marketable securities with $0.00 in debt, giving a net cash position of $4.18M billion.
- Cash & Marketable Securities
- $4.18M
- Total Debt
- $0.00
- Net Cash
- $4.18M
- Net Cash Per Share
- $1.73
- Tangible Book Value Per Share
- $0.43
Margins
Gross margin is 34.58%, with operating margin of -85.52%, and net profit margin of -234.53%.
- Gross Margin
- 34.58%
- Operating Margin
- -85.52%
- Pretax Margin
- -234.37%
- Net Profit Margin
- -234.53%
- EBITDA Margin
- -234.11%
- EBIT Margin
- -234.37%
Analyst Forecast
The average price target for Arcadia Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -12.24%
- EPS Growth Forecast
- 17.56%
Scores
- Smart Score
- ―
- AI Score
- 40
